Prostamax
also known as Lys-Glu-Asp-Pro, KEDP
Synthetic tetrapeptide (Lys-Glu-Asp-Pro) developed in the Khavinson bioregulator tradition for prostate-targeted tissue regeneration. Animal and organotypic culture data demonstrate prostatic tissue-specific stimulation, chromatin decondensation, and functional restoration in aged and BPH models. Acts as putative epigenetic regulator by deheterochromatinization, reversing age-related transcriptional silencing in target tissues.
At a glance
SQ · Protocol per Khavinson tradition
Primary target — Chromatin in prostatic cells — pericentromeric heterochromatin regions.
Pathway — Epigenetic modulation → heterochromatin decondensation → transcriptional derepression [dzhokhadze-2012].
Downstream effect — Increased sister chromatid exchange, Ag-NOR activation, reduced C-heterochromatin condensation; tissue-specific regenerative stimulation in prostate organotypic cultures [dzhokhadze-2012][zakutski-2006].
Origin — Synthetic tetrapeptide modeled on naturally occurring protein-derived bioregulators isolated between lysine-arginine motifs in long-lived species [khavinson-2017].
| Parameter | Value |
|---|---|
| Effective concentration (in vitro) | 0.05 ng/mL [zakutski-2006]Organotypic culture model; demonstrated tissue-specific stimulation. |
| Human clinical dose | Not establishedNo published human trials; dosing extrapolated from Russian clinical tradition (not peer-reviewed). |
| Evidence basis | Animal / organotypic culture [zakutski-2006][dzhokhadze-2012]No randomized controlled trials in humans. |
| Age groups studied | Young (3-week) and aged (18-month) rats; elderly humans (75–86 years) in vitro [zakutski-2006][dzhokhadze-2012] |
| Duration | Not specifiedKhavinson protocols typically 10–20 days per cycle; no long-term safety data. |
Reconstitution
A pure mass-to-volume utility. Enter what you have in the vial; the atlas computes the volume per dose. No prescription information.
Evidence base: Russian-language clinical literature, primarily from the St. Petersburg Institute of Bioregulation and Gerontology (Khavinson school), 1985 onward. Not extensively peer-reviewed in Western journals.
- — Active prostate malignancy — epigenetic modulation effects unknown in cancer
- — History of prostate cancer — theoretical concern re: transcriptional activation
- — Undiagnosed prostatic nodules or elevated PSA
- 01Route
Subcutaneous or intramuscular — per Khavinson bioregulator tradition. No published human pharmacokinetic data.
- 02Reconstitution
If lyophilised: reconstitute with sterile water per manufacturer protocol (not standardized in literature).
- 03Frequency
Typically daily or every-other-day in Russian clinical tradition; duration 10–20 days per cycle.
- 04Monitoring
No established biomarkers. Theoretical: PSA, prostate imaging, symptom scores (IPSS for BPH).
- 05Note
All protocols derived from non-peer-reviewed Russian clinical practice; Western regulatory approval absent.
Sources
of 38 rendered claims carry a resolvable citation.
- [dzhokhadze-2012]Dzhokhadze 2012 — [Deheterochromatinization of the chromatin in old age induced by oligopeptide bioregulator (Lys-Glu-Asp-Pro)].
journal, 2012 - [khavinson-2017]Khavinson 2017 — Peptides (Epigenetic Regulators) in the Structure of Rodents with a Long and Short Lifespan.
journal, 2017 - [kiladze-2009]Kiladze 2009 — Microcalorimetric study of human blood lymphocytes culture at presence of copper, cadmium and prostamax.
journal, 2009 - [zakutski-2006]Zakutskiĭ 2006 — [The tissue-specific effect of synthetic peptides-biologic regulators in organotypic tissues culture in young and old rats].
journal, 2006